Study: J&J and Bayer's anticoagulant Xarelto yields mixed results

04/5/2011 | Reuters

A clinical study found that Bayer and Johnson & Johnson's anticoagulant Xarelto worked as well as standard injectable drug Lovenox, by Sanofi-Aventis, in preventing blood clots after 10 days of treatment among patients hospitalized for acute illnesses. However, the incidence of bleeding among Xarelto users after 35 days of treatment was more than double the rate seen in Lovenox users.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID